Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
4(57%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
4
57%
Ph phase_3
1
14%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(3)

Detailed Status

Completed3
Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

completed343%
recruiting343%
active_not_recruiting114%

Recent Activity

4 active trials
Showing 5 of 7
active_not_recruitingphase_2

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

NCT06997367
recruitingphase_2

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.

NCT06272812
recruitingphase_2

Evaluating the Safety and Immunogenicity of MTBVAC

NCT05947890
completedphase_2

Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates

NCT03536117
recruitingphase_3

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

NCT04975178
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06997367Phase 2

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

Active Not Recruiting
NCT06272812Phase 2

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.

Recruiting
NCT05947890Phase 2

Evaluating the Safety and Immunogenicity of MTBVAC

Recruiting
NCT03536117Phase 2

Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates

Completed
NCT04975178Phase 3

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

Recruiting
NCT02933281Phase 1

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa

Completed
NCT02729571Phase 1

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7